Literature DB >> 28918073

A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.

Dawn P Wooley1, Priyanka Sharma2, John R Weinstein3, Poornima Kotha Lakshmi Narayan4, David V Schaffer5, Katherine J D A Excoffon6.   

Abstract

A directed evolution approach was used to select for Adeno-associated virus (AAV) capsids that would exhibit more tropism toward an HIV-1 producer T cell line with the long-term goal of developing improved gene transfer vectors. A library of AAV variants was used to infect H9 T cells previously infected or uninfected by HIV-1 followed by AAV amplification with wild-type adenovirus. Six rounds of biological selection were performed, including negative selection and diversification after round three. The H9 T cells were successfully infected with all three wild-type viruses (AAV, adenovirus, and HIV-1). Four AAV cap mutants best representing the small number of variants emerging after six rounds of selection were chosen for further study. These mutant capsids were used to package an AAV vector and subsequently used to infect H9 cells that were previously infected or uninfected by HIV-1. A quantitative polymerase chain reaction assay was performed to measure cell-associated AAV genomes. Two of the four cap mutants showed a significant increase in the amount of cell-associated genomes as compared to wild-type AAV2. This study shows that directed evolution can be performed successfully to select for mutants with improved tropism for a T cell line in the presence of HIV-1.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AAV; Directed evolution; Gene transfer; HIV-1; T cell

Mesh:

Year:  2017        PMID: 28918073      PMCID: PMC6112236          DOI: 10.1016/j.jviromet.2017.09.008

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  68 in total

1.  Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus.

Authors:  P X Zhang; R L Fuleihan
Journal:  Gene Ther       Date:  1999-02       Impact factor: 5.250

2.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

3.  Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.

Authors:  J A Hoxie; J D Alpers; J L Rackowski; K Huebner; B S Haggarty; A J Cedarbaum; J C Reed
Journal:  Science       Date:  1986-11-28       Impact factor: 47.728

4.  Origin of the HIV-susceptible human CD4+ cell line H9.

Authors:  D L Mann; S J O'Brien; D A Gilbert; Y Reid; M Popovic; E Read-Connole; R C Gallo; A F Gazdar
Journal:  AIDS Res Hum Retroviruses       Date:  1989-06       Impact factor: 2.205

5.  Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping.

Authors:  N V Somia; H Miyoshi; M J Schmitt; I M Verma
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells.

Authors:  B A Antoni; A B Rabson; I L Miller; J P Trempe; N Chejanovsky; B J Carter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

8.  Adeno-associated virus-mediated gene transfer.

Authors:  Arun Srivastava
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

9.  Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.

Authors:  Selvarangan Ponnazhagan; Gandham Mahendra; Sanjay Kumar; John A Thompson; Mark Castillas
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

10.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

View more
  4 in total

Review 1.  Vector engineering, strategies and targets in cancer gene therapy.

Authors:  Vijayata Singh; Nusrat Khan; Giridhara R Jayandharan
Journal:  Cancer Gene Ther       Date:  2021-04-15       Impact factor: 5.987

Review 2.  Optimization of AAV vectors to target persistent viral reservoirs.

Authors:  Rossana Colón-Thillet; Keith R Jerome; Daniel Stone
Journal:  Virol J       Date:  2021-04-23       Impact factor: 5.913

Review 3.  Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer.

Authors:  Cindy Y Kok; Lauren M MacLean; Jett C Ho; Leszek Lisowski; Eddy Kizana
Journal:  JACC CardioOncol       Date:  2021-12-21

Review 4.  Advances of adeno-associated virus applied in gene therapy to hemophilia from bench work to the clinical use.

Authors:  Xiaolei Pei; Mingzhe Han; Lei Zhang
Journal:  Blood Sci       Date:  2019-10-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.